

# Evidence Based Intervention

## Hybrid Closed Loop Systems for Children and Young People aged under 19 years

<b>Document Owner:</b>	Dr Rachel Joyce – Medical Director
<b>Document Author(s):</b>	Clinical Policies Group
<b>Version:</b>	v1.0
<b>Approved By:</b>	Commissioning Committee
<b>Date of Approval:</b>	11 <sup>th</sup> July 2024
<b>Date of Review:</b>	July 2025

### Change and Approval History:

Version	Revision Description	Reviewer / Approval Group	Date of Review / Approval





As per NICE TA943:

Only use HCL systems with the support of a trained multidisciplinary team experienced in CSII and continuous glucose monitoring in type 1 diabetes.

Only use HCL systems if the person or their carer:

- is able to use them, and
- is offered approved face-to-face or digital structured education programmes, or
- is competent in insulin dosing and adjustments.

**Where patients are eligible for a hybrid closed loop system, clinicians must choose the lowest cost system that is clinically appropriate for the patient and is included on the NHSE national framework.**

Currently, CamAPS FX is the only HCL algorithm licensed in children aged 1-2 years. HWE ICB would therefore expect a compatible HCL system incorporating CamAPS FX to be used in this group.

This position statement will be reviewed annually, or more frequently if new guidance is published or as required as part of the local phased roll-out of the relevant NICE TA and NHSE HCL 5 year implementation strategy.

## References

National Institute for Health and Care Excellence (2023) [TA943] Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes <https://www.nice.org.uk/guidance/ta943>

NHSE (2024) Hybrid closed loop technologies: 5-year implementation strategy <https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/>

NHS Supply Chain National Framework: Insulin Pumps, Continuous Glucose Monitoring and Associated Products <https://www.supplychain.nhs.uk/product-information/contract-launch-brief/insulin-pumps-and-associated-products/>

## DOCUMENT CONTROL

*This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the website.*

*□□Do you really need to print this document?*

*Please consider the environment before you print this document and where copies should be printed double-sided. Please also consider setting the Page Range in the Print properties, when relevant to do so, to avoid printing the policy in its entirety.*

